Abstract
NAIMIT (acronym for Natural Immune Modulation for Intervention in Type 1 Diabetes) is a large-scale collaborative programme of the 7th framework from the European Commission. The aim of the consortium is to bring together a group of leading European researchers spanning the field from genetics, through pancreatic beta-cell, dendritic cells and T-cell biology, towards clinical interventions. The ultimate goal is to develop novel and personalised interventional therapies in recent-onset type 1 diabetic patients, with minimal immune system interference, leading to beta-cell protection and restoration, based on a solid understanding of the disease pathogenesis, enabling experimental findings to be adopted for clinical applications.
Author supplied keywords
Cite
CITATION STYLE
Mathieu, C., Overbergh, L., Badenhoop, K., Bingley, P. J., Dayan, C. M., Demengeot, J., … Megit, S. (2014). The story of NAIMIT - A framework 7 project on type 1 diabetes. European Endocrinology, 10(2), 100–105. https://doi.org/10.17925/EE.2014.10.02.100
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.